Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis

被引：3
|
作者：
Sekeres, M. [1 ]
Swern, A. [2 ]
Fenaux, P. [3 ]
Greenberg, P. [4 ]
Sanz, G. [5 ]
Bennett, J. [6 ]
Dreyfus, F. [7 ]
Cazzola, M. [8 ,9 ]
List, A. [10 ]
Garcia-Manero, G. [11 ]
Li, J. Shiansong [2 ]
Sugrue, M. [12 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH 44106 USA
[2] Celgene Corp, Biostat, Summit, NJ USA
[3] Avicenne Hosp, Dept Clin Hematol, Bobigny, France
[4] Stanford Univ, Div Hematol, Stanford, CA 94305 USA
[5] Hosp Univ & Politecn La Fe Valencia, Dept Hematol, Valencia, Spain
[6] Univ Rochester, Div Hematopathol & Hematol Oncol, Med Ctr, Rochester, NY 14627 USA
[7] Univ Paris, Hop Cochin, Dept Hematol, F-75252 Paris, France
[8] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[9] Univ Pavia, I-27100 Pavia, Italy
[10] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, Tampa, FL 33612 USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[12] Celgene Corp, Med Affairs, Summit, NJ USA
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70152-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-104
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [31] Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry
    de Swart, Louise
    Smith, Alex
    Johnston, Tom
    Haase, Detlef
    Droste, Jackie
    Fenaux, Pierre
    Symeonidis, Argiris
    Sanz, Guillermo
    Hellstroem-Lindberg, Eva
    Cermak, Jaroslav
    Germing, Ulrich
    Stauder, Reinhard
    Georgescu, Otilia
    MacKenzie, Marius
    Malcovati, Luca
    Holm, Mette Skov
    Almeida, Antonio Medina
    Madry, Krzysztof
    Slama, Borhane
    Guerci-Bresler, Agnes
    Sanhes, Laurence
    Beyne-Rauzy, Odile
    Luno, Elisa
    Bowen, David
    de Witte, Theo
    BLOOD, 2013, 122 (21)
  • [32] IMPACT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RBC TRANSFUSION-DEPENDENT LOW-OR INT-1-RISK MYELODYSPLASTIC SYNDROMES WITH DEL5Q: A RANDOMIZED PHASE 3 STUDY (MDS-004)
    Brandenburg, N.
    Fu, T.
    Revicki, D.
    Knight, R.
    Muus, P.
    Fenaux, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 127 - 127
  • [33] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    A F List
    J M Bennett
    M A Sekeres
    B Skikne
    T Fu
    J M Shammo
    S D Nimer
    R D Knight
    A Giagounidis
    Leukemia, 2014, 28 : 1033 - 1040
  • [34] A RANDOMISED STUDY OF LENALIDOMIDE (LEN) plus /- EPO IN RBC TRANSFUSION DEPENDENT (TD) IPSS LOW AND INT-1 (LOWER RISK) MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL 5Q RESISTANT TO EPO
    Toma, A.
    Chevret, S.
    Kosmider, O.
    Delaunay, J.
    Stamatoullas, A.
    Rose, C.
    Beyne-Rauzy, O.
    Banos, A.
    Guerci-Bresler, A.
    Jourdan, E.
    Sardnal, V.
    Caillot, D.
    Laribi, K.
    de Renzis, B.
    Bordessoule, D.
    Slama, B.
    Sanhes, L.
    Fontenay, M.
    Fenaux, P.
    Dreyfus, F.
    HAEMATOLOGICA, 2013, 98 : 454 - 455
  • [35] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    List, A. F.
    Bennett, J. M.
    Sekeres, M. A.
    Skikne, B.
    Fu, T.
    Shammo, J. M.
    Nimer, S. D.
    Knight, R. D.
    Giagounidis, A.
    LEUKEMIA, 2014, 28 (05) : 1033 - 1040
  • [36] TREATMENT-EMERGENT ADVERSE EVENTS IN LENALIDOMIDE-TREATED LOW/INT-1-RISK MYELODYSPLASTIC SYNDROMES PATIENTS WITHOUT DEL(5Q) INELIGIBLE FOR OR REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS
    Almeida, A.
    Fenaux, P.
    Garcia-Manero, G.
    Giagounidis, A.
    Goldberg, S.
    Groepper, S.
    Jonasova, A.
    Mufti, G. J.
    Sanz, G. F.
    Vey, N.
    Castaneda, C.
    Zhong, J.
    Beach, C.
    Santini, V.
    HAEMATOLOGICA, 2016, 101 : 502 - 502
  • [37] A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO.
    Toma, Andrea
    Chevret, Sylvie
    Kosmider, Olivier
    Delaunay, Jacques
    Stamatoullas, Aspasia
    Rose, Christian
    Beyne-Rauzy, Odile
    Banos, Anne
    Guercy-Bresler, Agnes
    Jourdan, Eric
    Sardnal, Veronique
    Caillot, Denis
    Laribi, Kamel
    De Renzis, Benoit
    Bordessoule, Dominique
    Slama, Borhane
    Sanhes, Laurence
    Fontenay, Michaela
    Fenaux, Pierre
    Dreyfus, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    A F List
    J M Bennett
    M A Sekeres
    B Skikne
    T Fu
    J M Shammo
    S D Nimer
    R D Knight
    A Giagounidis
    Leukemia, 2015, 29 : 2452 - 2452
  • [39] MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q)
    Santini, V.
    Li, J. S.
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Hoenekopp, A.
    Beach, C. L.
    Skikne, B.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S59 - S59
  • [40] LENALIDOMIDE THERAPY IN MYELODYSPLASTIC SYNDROMES WITH LOW-OR-INTERMEDIATE-1 IPSS RISK AND DEL(5Q): RETROSPECTIVE STUDY OF 17 PATIENTS FROM A SINGLE INSTITUTION
    Finelli, C.
    Follo, M. Y.
    Barraco, M.
    De Maio, C.
    Testoni, N.
    Ottaviani, E.
    Parisi, S.
    Mongiorgi, S.
    Stanzani, M.
    Papayannidis, C.
    Cocco, L.
    Cavo, M.
    HAEMATOLOGICA, 2016, 101 : S119 - S119
12345